Androgen receptor activity in T cells limits checkpoint blockade efficacy-Reference-Cited by-同舟云学术

Androgen receptor activity in T cells limits checkpoint blockade efficacy

Published:2022-03-23 Issue:7915 Volume:606 Page:791-796
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Guan Xiangnan,Polesso Fanny,Wang Chaojie,Sehrawat Archana,Hawkins Reed M.^ORCID,Murray Susan E.,Thomas George V.^ORCID,Caruso Breanna^ORCID,Thompson Reid F.,Wood Mary A.,Hipfinger Christina,Hammond Scott A.,Graff Julie N.,Xia Zheng^ORCID,Moran Amy E.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-022-04522-6.pdf

Reference69 articles.

1. Beer, T. M. et al. Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J. Clin. Oncol. 35, 40–47 (2017).

2. Kwon, E. D. et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol. 15, 700–712 (2014).

3. Fong, P. C. et al. Pembrolizumab plus enzalutamide in abiraterone-pretreated patients with metastatic castrate resistant prostate cancer: cohort C of the phase 1b/2 KEYNOTE-365 study. J. Clin. Oncol. 37, suppl:abstr 5010 (2019)

4. Sharma, P. et al. Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 trial. Cancer Cell. 38, 489–499 (2020).

5. Antonarakis, E. S. et al. Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study. J. Clin. Oncol. 38, 395–405 (2020).

Cited by 208 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in and prospects of immunotherapy for prostate cancer;Cancer Letters;2024-10

2. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

3. Sex difference in human diseases: mechanistic insights and clinical implications;Signal Transduction and Targeted Therapy;2024-09-10

4. Immune system adaptation during gender-affirming testosterone treatment;Nature;2024-09-04

5. Androgens contribute to sex bias of autoimmunity in mice by T cell-intrinsic regulation of Ptpn22 phosphatase expression;Nature Communications;2024-09-03